APMD — Apnimed, Inc.

APMD closed at $18.95 (-0.21%) on Oct 26, 2026. Recent offering filing (424B4, Jul 2026). Float: 17.9M shares. Latest SEC filing: S-8 on Sep 8, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for APMD in the TickerWise workspace.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 65
• Website: https://apnimed.com

Latest SEC filings for APMD

• 2026-09-08S-8
• 2026-09-0810-Q
• 2026-09-088-K
• 2026-08-07SCHEDULE 13G
• 2026-08-038-K
• 2026-07-31EFFECT
• 2026-07-313
• 2026-07-31S-8
• 2026-07-31424B4
• 2026-07-31S-1MEF

Latest APMD news

• 2026-10-01Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7% Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.